ReviewHuman vaccines & immunotherapeutics2018
Influenza vaccines: Evaluation of the safety profile.
Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial.The Pediatric infectious disease journal · 2020Trial
- Symptoms associated with influenza vaccination and experimental human pneumococcal colonisation of the nasopharynx.Vaccine · 2020Trial
- Safety profile of India's influenza vaccine in a large-scale corporate vaccination drive.Human vaccines & immunotherapeutics · 2026Observational
- Update on the Efficacy of Vaccination on Host Immunity to Influenza Virus Infection.International archives of allergy and immunology · 2026Review
- Hydroxypropyl Cellulose Enhances Immune Responses to the Current Seasonal Influenza Vaccine in Mice.Microbiology and immunology · 2026Article
- Comparison of levels of satisfaction and rates of adverse events in different anatomical injection sites in outbound travelers: a randomized controlled trial.Tropical diseases, travel medicine and vaccines · 2026Article
- Acceptability of patient-centered digital vaccine safety monitoring: A Canadian Immunization Research Network study.Human vaccines & immunotherapeutics · 2025Article
- COVID-19 vaccination and use of antibiotics in COVID-19 patients: a systematic review and meta-analysis.Infection prevention in practice · 2025Review
- Vaccination in Chronic Obstructive Pulmonary Disease.Vaccines · 2025Review
- Novel vaccine strategies to induce respiratory mucosal immunity: advances and implications.MedComm · 2025Review
- Novel Antigen-Presenting Cell-Targeted Nanoparticles Enhance Split Vaccine Immunity Through Microneedles Inoculation.International journal of nanomedicine · 2025Article
- The impact of the COVID-19 pandemic and the free vaccination policy on seasonal influenza vaccination uptake among older adults in Ningbo, Eastern China.Human vaccines & immunotherapeutics · 2024Article
- IAPSM's Position Paper on Influenza Vaccines for Adult Immunization in India.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2024Article
- Knowledge, Attitudes, and Practices Regarding Influenza Vaccination Among Healthcare Workers in Saudi Arabia: A Cross-sectional Study.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024Article
- Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Chitosan non-particulate vaccine delivery systems.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Review
- Influenza vaccine coverage in 6months-64 years-old patients affected by chronic diseases: A retrospective cohort study in Italy.Human vaccines & immunotherapeutics · 2023Article
- Article
- Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations.Pharmaceutics · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The safety of vaccines is a critical factor in maintaining public trust in national vaccination programs. Vaccines are recommended for children, adults and elderly subjects and have to meet higher safety standards, since they are administered to healthy subjects, mainly healthy children. Although vaccines are strictly monitored before authorization, the possibility of adverse events and/or rare adverse events cannot be totally eliminated. Two main types of influenza vaccines are currently available: parenteral inactivated influenza vaccines and intranasal live attenuated vaccines. Both display a good safety profile in adults and children. However, they can cause adverse events and/or rare adverse events, some of which are more prevalent in children, while others with a higher prevalence in adults. The aim of this review is to provide an overview of influenza vaccine safety according to target groups, vaccine types and production methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.